Clinical study reveals persistent endogenous glucose production with combination therapy in type 2 diabetes, explaining why blood sugar levels do not synergistically drop.
These results demonstrate that liraglutide failed to block the increase in EGP caused by canagliflozin despite blocking the rise in plasma glucagon and preventing the decrease in plasma insulin concentration caused by canagliflozin. The failure of liraglutide to prevent the increase in EGP caused by canagliflozin explains the lack of additive effect of these two agents on HbA1c.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: